Modern management of Cardiometabolic continuum: from overweight/obesity to prediabetes/type 2 diabetes mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F24%3A00084971" target="_blank" >RIV/00023001:_____/24:00084971 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11140/24:10481952 RIV/00669806:_____/24:10481952

Result on the web

<a href="https://link.springer.com/content/pdf/10.1007/s13300-024-01615-5.pdf" target="_blank" >https://link.springer.com/content/pdf/10.1007/s13300-024-01615-5.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s13300-024-01615-5" target="_blank" >10.1007/s13300-024-01615-5</a>

Result language

angličtina

Original language name

Modern management of Cardiometabolic continuum: from overweight/obesity to prediabetes/type 2 diabetes mellitus. Recommendations from the Eastern and Southern Europe Diabetes and Obesity Expert Group

Original language description

The increasing global incidence of obesity and type 2 diabetes mellitus (T2D) underscores the urgency of addressing these interconnected health challenges. Obesity enhances genetic and environmental influences on T2D, being not only a primary risk factor but also exacerbating its severity. The complex mechanisms linking obesity and T2D involve adiposity-driven changes in beta-cell function, adipose tissue functioning, and multi-organ insulin resistance (IR). Early detection and tailored treatment of T2D and obesity are crucial to mitigate future complications. Moreover, personalized and early intensified therapy considering the presence of comorbidities can delay disease progression and diminish the risk of cardiorenal complications. Employing combination therapies and embracing a disease-modifying strategy are paramount. Clinical trials provide evidence confirming the efficacy and safety of glucagon-like peptide 1 receptor agonists (GLP-1 RAs). Their use is associated with substantial and durable body weight reduction, exceeding 15%, and improved glucose control which further translate into T2D prevention, possible disease remission, and improvement of cardiometabolic risk factors and associated complications. Therefore, on the basis of clinical experience and current evidence, the Eastern and Southern Europe Diabetes and Obesity Expert Group recommends a personalized, polymodal approach (comprising GLP-1 RAs) tailored to individual patient&apos;s disease phenotype to optimize diabetes and obesity therapy. We also expect that the increasing availability of dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists will significantly contribute to the modern management of the cardiometabolic continuum.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30202 - Endocrinology and metabolism (including diabetes, hormones)

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Diabetes therapy

ISSN

1869-6953

e-ISSN

1869-6961

Volume of the periodical

15

Issue of the periodical within the volume

9

Country of publishing house

DE - GERMANY

Number of pages

28

Pages from-to

1865-1892

UT code for WoS article

001269540300001

EID of the result in the Scopus database

2-s2.0-85198103917